SV2006002669A - Inhibidores de quinasa c-fms ref. prd2368 - Google Patents

Inhibidores de quinasa c-fms ref. prd2368

Info

Publication number
SV2006002669A
SV2006002669A SV2006002669A SV2006002669A SV2006002669A SV 2006002669 A SV2006002669 A SV 2006002669A SV 2006002669 A SV2006002669 A SV 2006002669A SV 2006002669 A SV2006002669 A SV 2006002669A SV 2006002669 A SV2006002669 A SV 2006002669A
Authority
SV
El Salvador
Prior art keywords
cancer
formula
diseases
compounds
treatment
Prior art date
Application number
SV2006002669A
Other languages
English (en)
Inventor
Carl Illig
Shelley Ballentine
Jinsheng Chen
Sanath Meegalla
M Jonathan Rudolph
Mark Wall
Ken Wilson
Renee Desjarlais
Christopher J Molloy
Carl Manthey
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SV2006002669A publication Critical patent/SV2006002669A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C07D307/71—Nitro radicals attached in position 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE LA FORMULA I: (VER FORMULA); EN LA CUAL A, X, R2 Y W SE DEFINEN EN LA MEMORIA DESCRIPTIVA, ASÍ COMO SOLVATOS, HIDRATOS, TAUTÓMEROS Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, QUE INHIBEN, LAS TIROSIN QUINASAS DE PROTEÍNA, ESPECIALMENTE LA QUINASA C-FMS. TAMBIÉN SE PROPORCIONAN MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES, Y ENFERMEDADES CON UN COMPONENTE INFLAMATORIO; TRATAMIENTO DE METÁSTASIS DE CÁNCER OVÁRICO, CÁNCER DE ÚTERO, CÁNCER DE MAMA, CÁNCER DE COLON, CÁNCER DE ESTÓMAGO, LEUCEMIA DE CÉLULA PILOSA Y CARCINOMA DE PULMÓN DE CÉLULA NO PEQUEÑA, Y EL TRATAMIENTO DE DOLOR, INCLUYENDO DOLOR ESQUELÉTICO CAUSADO POR METÁSTASIS TUMORAL U OSTEOARTRITIS, O DOLOR VISCERAL, INFLAMATORIO, Y NEUROGÉNICO, ASÍ COMO TAMBIÉN OSTEOPOROSIS, ENFERMEDAD DE PAGET Y OTRAS ENFERMEDADES EN LAS CUALES LA RESORCIÓN ÓSEA MEDIA LA MORBILIDAD INCLUYENDO ARTRITIS, PARO DE PRÓTESIS, SARCOMA OSTEOLÍTITO, MIELOMA, Y METÁSTASIS TUMORAL AL HUESO, CON LOS COMPUESTOS DE LA FORMULA I.
SV2006002669A 2004-10-22 2006-08-24 Inhibidores de quinasa c-fms ref. prd2368 SV2006002669A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62121104P 2004-10-22 2004-10-22
US67017205P 2005-04-11 2005-04-11
US11/254,276 US7662837B2 (en) 2004-10-22 2005-10-20 Inhibitors of c-fms kinase

Publications (1)

Publication Number Publication Date
SV2006002669A true SV2006002669A (es) 2009-10-15

Family

ID=40433511

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002669A SV2006002669A (es) 2004-10-22 2006-08-24 Inhibidores de quinasa c-fms ref. prd2368

Country Status (10)

Country Link
US (1) US7662837B2 (es)
AR (1) AR051599A1 (es)
EC (1) ECSP077409A (es)
IL (1) IL182735A (es)
MY (1) MY145668A (es)
NZ (1) NZ555289A (es)
PE (1) PE20060724A1 (es)
SV (1) SV2006002669A (es)
TW (1) TWI377942B (es)
UY (1) UY29178A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645755B2 (en) * 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
BRPI0710548B8 (pt) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
JP5480619B2 (ja) * 2006-04-20 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190541A (en) 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5702390A (en) 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
ATE248170T1 (de) 1999-01-11 2003-09-15 Univ Princeton Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP3222619A1 (en) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
IL150420A0 (en) 1999-12-28 2002-12-01 Pharmacopeia Inc Pyrimidine and triazine kinase inhibitors
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6613809B2 (en) * 2001-11-28 2003-09-02 The Regents Of The University Of California Metal-doped organic gels and method thereof
KR20050119201A (ko) 2003-04-09 2005-12-20 니뽄 다바코 산교 가부시키가이샤 ５원 헤테로방향족 고리 화합물 및 이의 의약적 용도
US7429603B2 (en) * 2003-04-25 2008-09-30 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7645755B2 (en) * 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase

Also Published As

Publication number Publication date
NZ555289A (en) 2010-10-29
MY145668A (en) 2012-03-15
ECSP077409A (es) 2007-05-30
IL182735A (en) 2013-10-31
TWI377942B (en) 2012-12-01
UY29178A1 (es) 2006-03-31
AR051599A1 (es) 2007-01-24
US7662837B2 (en) 2010-02-16
IL182735A0 (en) 2007-09-20
TW200630092A (en) 2006-09-01
PE20060724A1 (es) 2006-09-01
US20060148812A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
SV2006002669A (es) Inhibidores de quinasa c-fms ref. prd2368
CY1118879T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
CL2021002542A1 (es) Inhibidores de la proteína tirosina fosfatasa
CO7081155A2 (es) Inhibidores de serina/treonina cinasa
UA111933C2 (uk) Піролопіридини як інгібітори кінази
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
NI201000059A (es) Inhibidores de la cinasa c-fms.
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
PA8779701A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NI200900021A (es) Inhibidor de quinasa
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
BR112016015236A2 (pt) inibidores de serina/treonina quinase
EA201101497A1 (ru) Имидазопираны для применения в качестве ингибиторов киназ
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
AR079641A1 (es) Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis
CR10338A (es) Compuestos pirazolicos heterobiciclicos y metodos de uso
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
EA201101435A1 (ru) Имидазотиадиазолы для применения в качестве ингибиторов киназ
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren